PremiumThe FlyArmata reports data from Phase 1b/2a diSArm trial Armata Pharmaceuticals Inc (ARMP) Q1 Earnings Cheat Sheet Armata Pharmaceuticals receives $4.65M of funding from DoD PremiumThe FlyArmata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study Armata Pharmaceuticals Announces CMO Departure Agreement Armata Pharmaceuticals Extends Credit Agreement and CMO Departs PremiumCompany AnnouncementsArmata Pharmaceuticals VP Richard Rychlik Departs with Benefits Armata Pharmaceuticals Updates Progress and Corporate Presentation Armata Pharmaceuticals Welcomes David House as New SVP of Finance